Keywords

INFLUENZA – prevention and control
INFLUENZA, AVIAN – prevention and control
DISEASE OUTBREAKS – prevention and control
HEALTH PLANNING GUIDELINES
NATIONAL HEALTH PROGRAMS
REGIONAL HEALTH PLANNING
INTERNATIONAL COOPERATION
EMERGENCIES
VACCINES
EUROPE

Address requests about publications of the WHO Regional Office to:
• by e-mail
  publicationrequests@euro.who.int (for copies of publications)
  permissions@euro.who.int (for permission to reproduce them)
  pubrights@euro.who.int (for permission to translate them)
• by post
  Publications
  WHO Regional Office for Europe
  Scherfigsvej 8
  DK-2100 Copenhagen Ø, Denmark

© World Health Organization 2005

All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Where the designation “country or area” appears in the headings of tables, it covers countries, territories, cities, or areas. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. The views expressed by authors or editors do not necessarily represent the decisions or the stated policy of the World Health Organization.
## CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgements ....................................................................................................................</td>
</tr>
<tr>
<td>1. Introduction ........................................................................................................................</td>
</tr>
<tr>
<td>Objectives of the workshop .................................................................................................</td>
</tr>
<tr>
<td>Participants .........................................................................................................................</td>
</tr>
<tr>
<td>2. Opening session ................................................................................................................</td>
</tr>
<tr>
<td>3. Summaries of presentations ...............................................................................................</td>
</tr>
<tr>
<td>Overview of pandemic influenza .........................................................................................</td>
</tr>
<tr>
<td>Specific issue 1: Vaccines – where do we stand ...............................................................</td>
</tr>
<tr>
<td>Specific issue 2: Antiviral drugs – present view on usage in pandemic .........................</td>
</tr>
<tr>
<td>Pandemic preparedness: with the help of a checklist .......................................................</td>
</tr>
<tr>
<td>Pandemic influenza preparedness plans in Europe: summary of a questionnaire ............</td>
</tr>
<tr>
<td>4. Summaries from the working groups ...................................................................................</td>
</tr>
<tr>
<td>4.1 Working group 1: Preparing for an emergency (first component)...............................</td>
</tr>
<tr>
<td>4.2 Working group 2: Surveillance (second component), case investigation and treatment (third component) .................................................................</td>
</tr>
<tr>
<td>4.3 Working group 3: Preventing spread of disease in the community (fourth component), and Maintaining essential services (fifth component) .........................................................</td>
</tr>
<tr>
<td>4.4 Working group 4: Research and evaluation (sixth component), and Implementation, testing and revision of the plan (seventh component) .................................................................</td>
</tr>
<tr>
<td>4.5 Working group 5: Application of WHO checklist to country specific plans and identification of areas needing further consideration .............................................................</td>
</tr>
<tr>
<td>5. Workshop summary ...........................................................................................................</td>
</tr>
<tr>
<td>6. Conclusions .......................................................................................................................</td>
</tr>
<tr>
<td>7. Next steps .........................................................................................................................</td>
</tr>
<tr>
<td>Annex 1. Programme ...........................................................................................................</td>
</tr>
<tr>
<td>Annex 2. List of participants ...............................................................................................</td>
</tr>
</tbody>
</table>
Acknowledgements

The organizers of the workshop wish to stress the fruitful technical and financial collaboration between DG SANCO, the Health Threat Unit in particular, and the WHO Regional Office for Europe. Collaboration in the communicable disease area has dramatically evolved during the last two years, identifying common objectives and priorities which have been developed in synergy. WHO and the European Commission have in common the goal to protect the health of the European citizens, and the work being developed jointly in the area of pandemic preparedness planning has a high impact on the national systems and policies.

The workshop on pandemic influenza has seen the participation of all the Member States of the European Region proving that collaboration in this area is considered central to the partnership between Member States, the European Commission and WHO.

The success of this workshop could not have been achieved without the hard work of a group of dedicated and experienced experts from Europe and partner countries, such as Australia and Canada, who acted as facilitators (Ms Marja Esveld, Ms Jill Sciberras, Dr Anders Tegnell and Mr Jonathan Van Tam), Chair (Professor Ian Gust) and rapporteur (Dr Babatunde Olowokure). We would also like to acknowledge the key role played by the administrative staff of the two agencies.

We wish to thank the Government of Luxembourg for hosting this workshop.

1. Introduction

Influenza pandemics (worldwide epidemics) have occurred at irregular and unpredictable intervals, and have been associated with substantial morbidity, mortality and economic cost. The influenza A virus can cause pandemics and these occur as a result of changes in the virus leading to a sub-type to which no one has immunity, that can spread easily among humans and can give rise to serious disease. Appearance of such a subtype may lead to several simultaneous epidemics worldwide resulting in high numbers of cases and deaths and placing an immense burden on healthcare systems. With increasing globalization and urbanization, epidemics caused by a new influenza virus are likely to spread rapidly around the world. It is not possible to state when an influenza pandemic is likely to occur but the risk is considered real enough to justify preparations being made.

In response to the potential for a pandemic to occur influenza pandemic preparedness plans are being drawn up by Member states of the World Health Organization (WHO) and European Commission (EC). The Commission published in March 2004 its policy on the matter in a paper on Community Influenza Pandemic Preparedness and Response Planning. In addition, WHO has recently provided a guidance document for national pandemic plans.

Preparing for the next influenza pandemic requires multidisciplinary support and collaboration from partners at the local, national, regional and international levels. National preparedness planning is not a quick or simple process and will require time, a multisectoral approach, the involvement of communities and commitment from the highest political levels.
Following adoption by the EU Council of Ministries in June 2004 of the conclusions on the Commission paper on Community Influenza Pandemic Preparedness and Response Planning, and in support of WHO resolution EB.111R6, WHO and the EC jointly organized a two-day workshop on national pandemic influenza preparedness planning in Luxembourg from 2–3 March 2005. The European Commission hosted the workshop in Luxembourg.

**Objectives of the workshop**

The objective of pandemic preparedness planning is to enable countries to be prepared to recognize and manage an influenza pandemic. Planning will not prevent an influenza pandemic but is designed to reduce transmission of the pandemic virus strain and as a result reduce the health, social and economic consequences of a pandemic.

The specific objectives of this workshop were as follows.

- Facilitate the processes involved in influenza pandemic preparedness planning.
- Provide an opportunity for the discussion of priority components of a pandemic plan with colleagues and facilitators.
- Identify the way forward for WHO/EU Member States as they develop their pandemic plans.
- Identify whether further assistance is needed and if so, what form it should take.

**Participants**

The 60 participants included public health specialists, epidemiologists, communicable disease specialists, microbiologists, virologists, immunologists and preparedness planning specialists. They represented 50 WHO European regional member states and several entities. Representatives from the Ministry of Health Luxembourg, representing the current EU presidency, European Commission and WHO European Regional Office also participated in this event.

**2. Opening session**

Representatives from the Ministry of Health Luxembourg, WHO Regional Office for Europe and the European Commission welcomed workshop participants and gave opening speeches.

**Dr Danielle Hansen-König, Ministry of Health, Luxembourg**, welcomed participants and recognized the important contribution of the workshop to influenza pandemic preparedness in Europe. She also emphasized the importance of the workshop as a means of avoiding duplication and combining expertise and knowledge, particularly in common priority areas. She stressed the importance of the launch of the European Centre for Disease Control (CDC) in May 2005 as an important step for closer working between the EU and WHO. On behalf of the Luxembourg presidency of the EU Dr Hansen-König asked the participants to consider two specific aspects during the workshop. First, the possibility of common stockpiling and second, the upgrading of vaccine production capacity. The speaker wished the participants successful work and good results.
Dr Bernardus Ganter, WHO Regional Office for Europe, welcomed participants to the workshop on behalf of the Director of the Division of Technical Support, Dr Gudjon Magnusson and talked about the initial discussions between WHO and the EU that had led to this workshop. The workshop was seen as a further sign of the increased collaboration between the EU and WHO. He illustrated this with the revision process for the International Health Regulations (IHR) where the EU and WHO have worked together to reach a regional consensus for global health protection and the common position of all member states from the European Region was an important force to reach a global consensus. Dr Ganter also recognized the important role that the European CDC would play in the partnership between WHO and EU. He reminded participants that influenza pandemic preparedness planning was necessary for all countries as the virus as any infectious disease does not respect borders.

Dr Georgios Gouvras, European Commission, welcomed the participants of the workshop and thanked WHO for co-organizing the workshop. The speaker emphasized to participants the importance of pooling resources and working together for the common good. Dr Gouvras identified some issues considered to be a high priority for preparedness planning. These were management of outbreaks, performance of laboratories and the supply of vaccines and antiviral drugs. Referring to pandemic preparedness planning, the speaker highlighted how the EC and WHO had worked in partnership to encourage member states to develop and produce preparedness plans. Dr Gouvras emphasized that the key component of preparedness was the drawing up of a plan. He informed participants that later in 2005 an EU-wide exercise would be conducted to test the early warning and response measures that were in place for an influenza pandemic. Dr Gouvras stated that the best way forward in terms of vaccines was to work with vaccine manufacturers in a public private initiative in order to ensure more rapid vaccine production. The speaker wished all the participants of the workshop a fruitful discussion.

3. Summaries of presentations

Presentations were made on the morning of the first day providing background information for the workshop participants on a number of topics, and a summary of these are provided below. On the second day the morning session started with country presentations on preparedness from the United Kingdom, Canada and Kazakhstan. These, as well as the presentations from the first day, may be accessed at http://forum.europa.eu.int/Members/irc/sanco/phab/home.

Overview of pandemic influenza

Presented by: Dr Klaus Stöhr, WHO Global Influenza Programme, WHO Headquarters, Switzerland.

This presentation provided an overview of pandemic influenza, public health interventions and actions for preparedness. Dr Stöhr reviewed previous pandemics and their impact and stated that although another influenza pandemic will certainly occur it was not certain that it would be due to H5N1. The speaker emphasized that national pandemic preparedness was key and that all countries should use this window of opportunity to act now. A number of public health interventions that could be used were mentioned. There was also a focus on actions that could be taken in support of preparedness particularly those that would be globally beneficial.
Specific issue 1: Vaccines – where do we stand

Presented by: Dr Klaus Stöhr, WHO Global Influenza Programme, WHO Headquarters, Switzerland.

Dr Stöhr provided a historical view of vaccine availability during previous pandemics and showed that increased vaccine production takes months to occur and that supply could not meet demand. The speaker mentioned that 65%-70% of global vaccine capacity is located within 5 countries in Europe and that approximately 50% of that production is exported outside Europe. A number of challenges to vaccine production were also highlighted. This included the inability of current manufacturing capacity to meet projected demand with a 6-8 month period required for a vaccine to be produced against a pandemic strain of influenza. Dr Stöhr remarked that progress was being made to address these issues and clinical testing of candidate vaccines would soon commence. The speaker emphasized that vaccines are only one tool and that they may only be accessible to a minority of countries. Therefore consideration should be given to other public health interventions.

Specific issue 2: Antiviral drugs – present view on usage in pandemic

Presented by: Dr Klaus Stöhr, WHO Global Influenza Programme, WHO Headquarters, Switzerland.

The speaker indicated that there were significant problems with rapid and large-scale production and equitable access to antiviral drugs and plans for both increased production and stockpiling were required. With regard to production, Dr Stöhr mentioned that the production capacity of oseltamivir had increased fourfold recently as around a dozen countries had placed orders. Stockpiling is possible but only likely in more developed countries. WHO maintains a small stockpile for treatment and prophylaxis in affected countries.

Pandemic preparedness: with the help of a checklist

Presented by: Ms Marja Esveld, Health Care Inspectorate, Netherlands.

Ms Esveld worked through the various components of the plan stressing a number of areas including gaining political commitment, risk assessment, legal and ethical issues, communication and infection control guidelines for healthcare settings and laboratories. Preparedness planning should be viewed as a priority and a good investment, and it was indicated that a major area of work would be preparing the public. They need to be consulted, involved and reliably informed of what a pandemic will mean and what they can do to reduce its impact. Ms Esveld emphasized that the only thing more difficult than planning would be explaining why you did not do it. The speaker also mentioned the need to evaluate and revise plans based on new knowledge. Participants were introduced to the new phases in the WHO preparedness plan and they were asked to take these changes into consideration when writing or revising their plans.
Pandemic influenza preparedness plans in Europe: summary of a questionnaire

Presented by: Dr Massimo Ciotti, WHO secondment to the Health Threats Unit, European Commission, Luxembourg.

Dr Ciotti stated that prior to the workshop, background research was completed on influenza pandemic preparedness planning in Europe by analysing the results of a questionnaire sent to all member states of the WHO European region. This included 25 EU member states. There was a 100% response rate from the EU member states and 31 non-EU states and entities responded. The speaker indicated that there was great variability in completeness of the plans and none was 100% complete. When examining different components of the plan surveillance appeared to be relatively well developed while only a few countries had tested their plans. Dr Ciotti reminded participants that they should take into consideration how their plans fitted within the wider international context.

More detailed results from the questionnaire may be accessed at: http://www.eurosurveillance.org/ew/2005/050303.asp#1

4. Summaries from the working groups

After presentations on the first day participants were divided into four working groups, each covering one or more components of the WHO checklist for influenza pandemic preparedness planning (http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_4/en/). All participants rotated to each of the working groups.

After the country presentations on the second day, participants were divided into five working groups based on geographic proximity (working group 5). Each working group was then to examine their country’s pandemic planning, identify gaps and discuss priorities with colleagues. Section 4.5 provides a summary of the issues discussed at these workshops.

No attempt has been made to edit themes that recurred in different workshops.

4.1 Working group 1: Preparing for an emergency (first component)

It was noted that pandemic preparedness planning required resources and making difficult choices that would affect the whole community.

Participants’ discussion focused on four main issues.

4.1.1 Command and control

- Obtaining the collaboration of private healthcare practitioners and facilities.
- The difficulty in maintaining clarity of purpose and focus on issues as people involved in pandemic planning are constantly changing.
- There is a lack of clarity as to who should be members of planning and preparedness committee’s, which organization should lead and which organizations have the authority to make decisions.
• Lack of documentation of command and control structures.
• Few member states have carried out proper risk assessments.

4.1.2 Communication
• Involving the public in preparedness planning.
• Involving communities in preparedness planning.
• Some participants wondered whether people have been overwhelmed with messages regarding a likely influenza pandemic and that this might be counter-productive.
• Communication problems may occur between general practitioners and public health departments.
• Some felt that the issue of the pandemic was remote and that there had been too many plans in recent years (e.g. smallpox, anthrax, SARS) demanding time and resources. It was felt that all necessary tools for the pandemic should be prepared and then provided closer to the time. Education should continue at a low level and then be stepped up when a pandemic has been recognized.

4.1.3 Commitment
• Real commitment is required from governments not just the provision of money.
• Lack of specific support from the government.
• A challenge is to know when to start involving government.
• Identifying political opportunities in order to promote preparedness planning.

4.1.4 Legal and ethical issues
• Establishing whether ethical aspects should be explicitly addressed, implied or ignored in pandemic preparedness plans.
• Ensuring that those designated to receive antiviral drugs actually receive them.
• There is not sufficient guidance regarding who is responsible for tourists/visitors during a pandemic.
• Pharmaceutical companies are not selling antiviral drugs for stockpiling to member states with ‘small’ populations.
• The role of private insurance companies needs to be addressed.

4.2 Working group 2: Surveillance (second component), case investigation and treatment (third component)

A number of participants indicated that they had data gathering systems that were already well developed and used a variety of objective indicators.

Working group participants described the main issues:
4.2.1 Surveillance

- Establishing which surveillance systems are already in place.
- Some governments demanding daily reporting of indicators for influenza, or influenza-like illness. Resources not sufficient for this or systems not set up for this.
- The utility of daily reporting was questioned.
- Reliability of the data and using a small number of indicators.
- Politicians do not always respond in a timely manner to data provided and many do not realize the seriousness of a potential influenza pandemic.
- Clarity is required regarding the role of the European CDC.
- Lack of access to financial resources.
- An excessive focus on H5N1 and ignoring influenza A/H2 viruses.

4.2.2 Case investigation and treatment

- Laboratory reporting is poorly developed in some areas.
- Diagnostic capacity very poor in some countries and poorly resourced.
- Reference laboratories lacking in some sub-regions.
- No recommendations available on which patients should be tested or how many.
- Need to strike the right balance between public health and individual rights.
- Complacent attitudes of member states who do not have direct flight links to or from Asia.
- Clinical guidelines are recognized as necessary but compliance may be a problem.

4.3 Working group 3: Preventing spread of disease in the community (fourth component), and Maintaining essential services (fifth component)

Discussions in this working group highlighted a number of issues.

4.3.1 Preventing spread of disease in the community

- Lack of an evidence base for many of the measures proposed.
- Lack of guidance on the use of masks.
- Individual stockpiling of masks.
- Timing of explanation regarding reasons for defining ‘essential services’, ‘key persons’ and ‘high-risk groups’.
- Timing of messages.
- Maintaining levels of awareness regarding public health measures.
- Available legal frameworks inadequate. Legislation applies to sick people rather than well people. Legal framework also applies to emergencies and persons who have an infectious disease, but may want to apply ‘social distance and quarantine’ earlier.
- Complex issue – needs collaboration between different agencies.
• EC and WHO role in helping to enforce ‘social distance and quarantine measures’ across international borders is unclear.
• Establishing when to institute and when to stop public health measures and who will provide the information required.
• Ensuring that the International Health Regulations are integrated into legal framework.
• WHO will need to provide leadership in this area particularly if influenza vaccine producing countries embargo export of vaccine during a pandemic.
• Ensuring influenza vaccine supply for member states with ‘small’ populations.
• Uncertainty as to whom antiviral drugs should be given to, how they should be used and whether they will be given and used appropriately.
• Individuals who buy and keep their own supply of antiviral drugs.
• Legal aspects of writing prescriptions for drugs that are for an event that may occur sometime in the future.

4.3.2 Maintaining essential services
• Many hospitals have contingency plans but it is not clear how many patients they can cope with.
• No clear connection between public health and structures outside health care and public health.
• Logistics of delivering stockpiles to hospitals and other healthcare facilities during the pandemic.
• Defining the ‘other’ essential services.
• Defining ‘key workers’.
• Deciding which agency is in charge.

4.4 Working group 4: Research and evaluation (sixth component), and Implementation, testing and revision of the plan (seventh component)

It was noted that plans needed to be considered as ‘living’ documents in order for them to work beyond their initial implementation and that including testing, evaluation and revision of the plan as an integral part of preparedness activities was essential for this. There was little discussion about the role of research.

4.4.1 Discussion focused on four main issues related to preparedness plans
• Usable – is the plan properly structured and organized?
• Recognizable – are stakeholders aware of the plan?
• Flexible – can the plan support local variations?
• Applicable – does the plan reflect current knowledge?
4.4.2 Despite progress in a number of areas, a number of problems were identified

- Resources are required to carry out meaningful evaluation and revision.
- Many member states and entities did not have formal testing or evaluation strategies in place.
- High staff turnover results in a lack of progress as institutional knowledge is regularly lost.

4.5 Working group 5: Application of WHO checklist to country specific plans and identification of areas needing further consideration

This workshop took place on the second day and participants were divided into five working groups based on geographic proximity. Discussions covered a broad range of issues and these have been grouped under the various components of the WHO checklist for influenza pandemic preparedness planning.

4.5.1 Preparing for an emergency

- WHO and EU assistance needed to ‘unlock’ resources.
- WHO and EU should ensure that they communicate equally with all member states.
- EU should ensure that there are mechanisms in place for rapid communication and information exchange between all Member States.
- Not clear in many member states who makes decisions when an influenza pandemic occurs.
- Despite some plans only recently being completed they will be revised and updated following this workshop.
- Ethnic minorities should not be forgotten and may require special educational measures.
- EU and WHO asked to directly contact governments in order to gain support for preparedness planning and the implementation of such plans.

4.5.2 Surveillance

- Lack of sensitive early warning systems for influenza in a number of member states.
- Clarity is required regarding the role of the EISS (European Influenza Surveillance Scheme).
- Laboratory biosafety.

4.5.3 Case investigation and treatment

- Diagnostic capacity needs strengthening. This would be enhanced by the creation of more reference laboratories.
4.5.4 Preventing spread of disease in the community

- Implementing travel restrictions.
- Member states with ‘small’ populations are concerned regarding the difficulties experienced in securing suitable reserves of antiviral drugs and their ability to obtain vaccines during a pandemic.
- Individual stockpiling.
- Ensuring vaccine availability for purchasing countries during a pandemic.
- Legal issues surrounding licensing and use of vaccines produced during a pandemic.

4.5.5 Maintaining essential services

- Defining essential services and key workers.
- Infection control did not appear to be well understood.

4.5.6 Research and evaluation

- WHO should have a clear programme for research and development of a new generation of influenza vaccines.
- WHO should strengthen antiviral programme and have a special meeting to discuss this issue.

4.5.7 Implementation, testing and revision of the plan

- A forum is required to share plans at a later date.

5. Workshop summary

Presentations were made providing background information to the workshop participants on a number of topics on the first day. On the second day country presentations on preparedness were made.

Through a series of working groups participants discussed priority areas to be addressed using components of the WHO checklist. They also evaluated their own plans, as well as those of others, using the same checklist. Many of the issues identified centred around the following themes: political commitment, influenza surveillance, vaccine development and production, vaccine use and coverage, antiviral chemoprophylaxis and therapy, communication and financial and policy support.

Substantially reducing the impact of a pandemic will require member states to maximize the availability and use of both vaccines and antiviral drugs. This requires planning, not only at the national level but also at the regional and global level. Influenza vaccines are the most effective defence against influenza but because most influenza vaccine is produced in only a small number of countries vaccines will be in short supply during a pandemic, as will antiviral drugs. Ensuring adequate production and equitable distribution of these products will provide a serious challenge to global health protection when the next influenza pandemic occurs. Pandemic preparedness will therefore require close collaboration between the public and private sectors. The EU and WHO are currently in discussions with the pharmaceutical industry regarding enhanced
production capacity, research and licensing issues. However, it should be remembered that vaccines and anti-viral drugs are only two of the measures that can be used and that their supply and distribution will not keep pace with a pandemic.

Influenza pandemics have occurred at irregular and unpredictable intervals throughout history and it is expected that another pandemic will occur at an unknown date in the future. Concerns have been expressed that predictions of a pending pandemic are speculative and that media hype has been used to promote the expectation that the next pandemic is close. There seems to be little political interest in spending time, effort and financial resources in planning for an event that might not happen in the immediate or distant future particularly when there is the belief that more pressing and immediate issues need to be dealt with. It is also not clear when a pandemic will occur but it will certainly happen. It is also not clear whether the next pandemic will be due to H5N1 or another strain of influenza. It is however certain that when a pandemic does occur it will affect everyone and will not respect national borders. A pandemic will eventually result in health systems being stretched, economic losses, ethical dilemmas and social disruption. These and other impacts associated with a pandemic can only be reduced by careful planning.

This workshop has reinforced the need to develop concerted and co-ordinated actions to facilitate the planning and implementation of comprehensive pandemic preparedness plans. Member states will need to pay particular attention to the complexity of such a task and ensure that they adequately address risk assessment, public concern, partnerships, resource issues and co-ordination in their plans. As a result of this complexity there is a need for a periodic forum to exchange information and experiences in pandemic preparedness planning.

6. Conclusions

Several member states have completed plans and gained political commitment for their implementation. Member states that did not have published plans were either at the draft stage or had not started preparing them. This workshop made significant progress in building relationships within and between member states and providing a forum for the exchange of ideas and lessons learned from preparing and implementing plans. In doing so, the workshop achieved its objectives. However, the clear message was that there is a strong need for political commitment, increased resources for pandemic preparedness, more research and the resolution of complex legal and ethical issues.

Workshop participants identified a number of issues that require resolving, some common to all, others unique to some. In broad terms, participants expressed a strong interest in developing common solutions and cross-border co-operation. Further steps following the workshop will be to test and evaluate the readiness of member states. Member states do however need to prepare logistically and ensure that when plans are made or revised that they take into account the gaps identified using the WHO checklist.

It is acknowledged that the willingness of some member states to prepare for the pandemic is tempered by the complexity of such an effort and the unpredictability of the influenza virus. However, all countries need to consider implementing pandemic preparedness plans as a pandemic will affect everyone. It was also noted from the discussions that larger countries with complex political-administrative systems may need more work on preparedness planning particularly in the areas of responsibilities and communications. Smaller countries face other
difficulties such as access to expensive laboratory diagnostics, personal protection equipment. For these countries, the purchase of small amounts of vaccines and anti-viral drugs may also result in significant costs compared to large amounts.

WHO was asked to provide more information to Member States as it becomes available, particularly information not yet published in peer reviewed scientific journals. This could be made available for a restricted number of people via a secure website. Additionally there is a need to invite Member States to document any other health measures not related to medical treatment, such as isolation, quarantine and social distancing. The need to review the application of anti-viral drugs was expressed and mathematical modelling could provide useful information on the use of anti-viral drugs during localized transmission. The EC and WHO are collaborating in order to achieve the common objective of reducing the impact of an influenza pandemic and will continue to provide support to Member States as necessary.

7. Next steps

7.1 The workshop report and presentations made at the workshop are available online at [http://forum.europa.eu.int/Members/irc/sanco/phab/home](http://forum.europa.eu.int/Members/irc/sanco/phab/home).

7.2 The workshop report will be sent to participants, EU member states, WHO Regional Office for Europe member states and entities and other WHO Regional Offices.

7.3 Organization of follow-up workshops, especially in the area of risk assessment, management and communication and/or to fill specific needs in areas such as surveillance, reporting systems and laboratory diagnostics.

7.4 Review of progress made by member states in pandemic preparedness planning by a questionnaire survey in six months. The survey will use the same questionnaire as during the initial assessment.

7.5 Provision of support to member states that are experiencing difficulty in preparing plans, including the identification of training needs.

7.6 EU-wide exercise to test pandemic early warning and response measures planned for the fall of 2005.

7.7 More detailed assessment of different components of preparedness plans including virologic and disease-based surveillance systems.

7.8 Promote research to improve detection of new variants, to accelerate the development and availability of existing and novel vaccines and antiviral agents and evaluate the effectiveness of non-medical interventions.

7.9 Strengthen ties and collaborative links between the EC and WHO.

7.10 Strengthen ties and collaborative links between the European CDC and WHO.

7.11 Member states to carefully plan their communications strategies.

7.12 Review the possibility of the EU purchasing and maintaining a stockpile of antiviral drugs made available to any area within European Community.
Annex 1

PROGRAMME

Day 1

08.30–09.00 Registration

09.00–09.25 Opening
   Director Danielle Hansen-König
   Dr Gudjon Magnusson
   Mr Georgios Gouvras

09.25–09.30 Election of officers (chairman and rapporteur)
   Dr Bernardus Ganter

09.30–10.00 Overview of pandemic influenza
   Dr Klaus Stöhr

10.00–10.30 Specific issue 1: Vaccines – where do we stand
   Dr Klaus Stöhr

10.30–11.00 Coffee

11.00–11.30 Specific issue 2: Antivirals – present view on usage in pandemic
   Dr Klaus Stöhr

11.30–12.15 Presentation of WHO checklist and information of available WHO and EU background documents
   Dr Marja Esveld

12.15–12.30 Presentation of responses to the questionnaire
   Dr Massimo Ciotti

12.30–12.45 Overview of the procedures of the working groups, explanation of template to be used in the workshop, logistics, etc
   Dr Peet Tüll and Dr Franz Karcher

12.45–14.00 Lunch

14.00–16.00 Working group I
   To review the five themes in the WHO checklist
   Dr Marja Esveld
   Dr Anders Tegnell
   Ms Jill Sciberras
   Dr Jonathan Van-Tam

16.00–16.30 Coffee

16.30–18.30 Working group I (cont.)
Day 2

09.00–10.30 Country presentations – three examples
   Dr Jane Leese, UK
   Dr Botakoz Abdirova, Kazakhstan
   Ms Jill Sciberras, Canada

10.30–11.00 Coffee

11.00–12.45 Working group II
   Each country representative works through the checklist to identify gaps of planning and needs for further consideration, contacts and/or development in their respective country

12.45–14.00 Lunch

14.00–15.00 Working group II (cont.)

15.00–15.30 Coffee

15.30–16.00 Rapporteur’s report

16.00–16.30 General comments and follow-up proposals from EC and WHO

End of meeting
LIST OF PARTICIPANTS

ALBANIA
Professor Eduard KAKARIQI
Head
Department of Epidemiology
Institute of Public Health
Rruga ‘Alexander Moisiu’ 80
Tirana, Albania
Tel: +355 4 36 3553
Fax: +355 4 37 0058/9
E-mail: edikakarriqi@yahoo.com, ekakarriqi@ishp.gov.al, edikakarriqi@hotmail.com

ANDORRA
Dr. Mireia COLOM I SOLE
Public Health Technician
Department of epid. surveillnace
Ministry of Health
Av. Princep Benlloch, 30 - 4rt
AD-500 Andorra la Vella
Andorra
Tel: +376 860 345
Fax: +376 861 933
E-mail: mireiacolom@andorra.ad

Dr. Gemma Cumelles BASSOLS
Public Health Technician
Dept. of Epid. Surveillance
Ministry of Health
Av. Princip Benlloch 30 - 4 rt
AD-500 Andorra la Vella
Andorra
Tel: +376 860 345
Fax: +376 861 933
E-mail: gcumelles@andorra.ad

ARMENIA
Professor Vladimir DAVIDYANTS
Head State Sanitary Doctor
Ministry of Health
Republican Square, office207, Gov build3
375010 Yerevan
Armenia
Tel: +374 1 58 0303
Fax: +374 1 56 2783
E-mail: drd@armhealth.am
**AUSTRIA**
**Dr. Reinhild STRAUSS**
Bundesministerium für Gesundheit und Frauen (BMGF)
Generaldirektion Öffentliche Gesundheit
Radetzkystraße 2
A-1030 Wien
Tel: +43 1 71100 4367
Fax: +43 1 715 7312
Emergency phone: +43 664 13 22 163
E-mail: reinhild.strauss@bmgf.gv.at

**AZERBAIJAN**
**Dr. Akif ALIBAYOV**
Deputy
Sanitary-Epidemiological Surveillance Inspection
Ministry of Health
Kichik Deniz Str. 4
**AZ-1014 Baku**
Azerbaijan
Tel: +994 12 493 1033
Fax: +994 12 498 7260
E-mail: fma@who.baku.az

**BELARUS**
**Dr. Anatoly KOZHEMYAKIN**
Chief Epidemiologist
Ministry of Health
Mjasnikova Str. 39
**220048 Minsk**
Belarus
Tel: +375 172 206 356
Fax: +375 172 226 297
E-mail: echaika@healthmed.by

**BELGIUM**
**Dr. Monique COPPENS**
Health Warning Unit
Federal Public Service Public Health, Food Chain Safety and Environment
C.A.E. – Building Vésale 211
Montagne de l’Oratoire 20, box 3
1000 Bruxelles
Tel: +02 210 50 01, +32 472 95 84 42
Fax: +02 210 47 45
E-mail: monique.coppens@health.fgov.be
BOSNIA AND HERZEGOVINA
Dr. Janja BOJANJIC
Epidemiologist
Ministry of Health
Repulika Srpska
Jovana Ducica 1
78000 Banja Luka
Bosnia and Herzegovina
Tel: +387 51 216 509
Fax: +387 51 216 601
E-mail: higija2@inecco.net

Dr. Jelena RAVLIJA
Epidemiologist
Federal Public Health Institute
Ministry of Health
Kralja Zvonimira 17D
88000 Mostar
Bosnia and Herzegovina
Tel: +387 36 347 137
Fax: +387 36 324 687
E-mail: jelena.ravlija@tel.net.ba

BULGARIA
Professor Mira KOJOHAROVA
Head of Department ESEW
National Center for Infectious and
Parasitic Diseases
Ministry of Health
26 Yanko Sakazov Blvd.
1504 Sofia
Bulgaria
Tel: Mobile +359 887 916 549 Fax/Phone +359 2 846 55 17
Fax:+359 2 846 55 17
E-mail: mkojouharova@ncipd.netbg.com

CROATIA
Dr. Ira GJENERO-MARGAN
Head
Epidemiology of Infectious Disease
NIPH
 Croatian National Institute of Public
Health
Rockefellerova Str. 7
HR-10000 Zagreb
Croatia
Tel: +385 1 46 83 004
Fax: +385 1 46 83 877
E-mail: ira.gjenero-margan@hjiz.hr
**CYPRUS**
Dr. Emmelia VOUNOU  
Medical Officer Class A  
Medical and Public Health Services  
Ministry of Health  
10, Markou Drakou  
1449 Nicosia  
Cyprus  
Tel: +357 994 36 222  
Fax: +357 25774700  
E-mail: evounou@cytanet.com.cy

**CZECH REPUBLIC**
Jitka CASTKOVA MD  
Head, Epidemiological Department  
Center of Epidemiology and microbiology NIPH  
Srobarova 48  
10042 Praha 10  
Tel. +420 2 6708 2250  
Fax: +420 26708 2538  
E-mail: jcastkova@szu.cz

**ESTONIA**
Dr. Kuulo KUTSAR  
Chief Epidemiologist  
Health Protection Inspectorate  
81 Paldiski mnt  
EE-10617 Tallinn  
Tel: +372 694 35 06  
E-mail: kuulo.kutsar@tervisekaitse.ee

**FINLAND**
Mr Thedi ZIEGLER  
National Public Health Institute  
Mannerheimintie 166  
FIN-00300 Helsinki  
Tel: +358 9 47448348  
Fax: +358 9 47448355  
E-mail: thedi.ziegler@ktl.fi

**FRANCE**
Dr. Olivier BRAHIC  
Preparedness Planning  
Département des situations d’urgence sanitaire  
Direction générale de la santé  
Ministère des solidarités, de la santé et de la famille  
14 avenue Duquesne  
75350 Paris 07 SP  
France  
Tel: 01 40 56 71 99  
Fax: 01 40 56 56 54  
E-mail: olivier.brahic@sante.gouv.fr  
www.sante.gouv
GEORGIA
Dr. Paata IMNADZE
Director
National Center for Disease Control
M. Asatiani Str. 9
0102 Tbilisi
Georgia
Tel: +995 32 39 89 46
Fax: +995 32 43 30 59
E-mail: pimnadze@ncdc.ge

GERMANY
Dr. Martin KÜFER
Bayerisches Staatsministerium für Umwelt, Gesundheit und Verbraucherschutz
Abteilung 3 - Gesundheit Ref. 33 - Infektionsschutz, Hygiene
Rosenkavalierplatz 2
D-81925 München
Tel: +49 89 9214 2429
E-mail: martin.kuefer@stmugv.bayern.de

Dr. Walter H. HAAS
Fachgebiet 33 - Respiratorische Erkrankungen und Impfprävention
Robert Koch-Institut
Nordufer 20
D-13353 Berlin
Germany
Tel: +49 30 4547 3431
Fax: +49 30 4547 3533
E-mail: HaasW@rki.de

Dr. Angela WIRTZ
Hessisches Sozialministerium
Referat für Seuchenhygiene
Dostojewskistraße 4
D-65187 Wiesbaden
Tel: +49 0611 / 817 3336
E-mail: A.Wirtz@hsm.hessen.de

Dr. Matthias PULZ
Niedersächsisches Ministerium für Soziales, Frauen, Familie und Gesundheit
Hinrich-Wilhelm-Kopf-Platz 2
D-30159 Hannover
Tel: +49-511-120 4214.
E-mail: Matthias.Pulz@ms.niedersachsen.de

GREECE
Dr. Georgia SPALA, MD
Dept for Surveillance and Intervention
Office for Respiratory Diseases
Hellenic Centre for Infectious Diseases Control
Tel: +30-210-8899 024, +30 210 8899000
Fax: 30 210 8818868
E-mail: georgia@keel.org.gr
HUngary
Dr. György BERENCSI
Head of Department
National Center for Epidemiology
Gyáli 6
HU-1093 Budapest
Tel: +36 1 476 1264
Fax: +36 1 476 1368
E-mail: berencsigy@oek.antsz.hu

Iceland
Dr. Gudrun SIGMUNDSDOTTIR
Centre for Infectious Disease Control
Directorate of Health
Austurstrond 5
170 Seltjarnarnes
Iceland
Tel: +354 510 1910
E-mail: Gudrun@Landlaeknir.is

IRELAND
Dr. Derval IGOE
Specialist in Public Health Medicine,
Health Protection Surveillance Centre
25-27 Middle Gardiner Street,
Dublin 1, Ireland
Tel: + 353 1 8765300
E-mail: derval.igoe@mailx.hse.ie

ISRAEL
Mr Shemuel REZNIKOVICH
Adviser to the Head of
Public Health Service
Ministry of Health
14, Adam Hacohen Street
32714 Haifa
Israel
Tel: +972 57 7242 319
Fax: +972 9 8355 897
E-mail: gnt_sreznik@matat.health.gov.il

ITALY
Dr. ssa Maria Grazia POMPA, MD
Director, Communicable Diseases Unit
Directorate General of Health Prevention
Ministry of Health
Via della Civiltà Romana, 7
00144 Rome - ITALY
Tel: +39 06 5994 3905
Fax: +39 06 5994 3096
E-mail: m.pompa@sanita.it
KAZAKHSTAN
Dr. Botakoz ABDIROVA
Chief Specialist
Epidemiological Department
Ministry of Health
Moskovskaya Str. 66
473000 Astana
Kazakhstan
Tel: +7 3172 31 72 62
Fax: +7 3172 31 72 62
E-mail: zdrav@minzdrav-rk.kz

LATVIA
Dr. Dace VILUMA
Head of Unit
Epidemiological Safety, Food Safety and Nutrition
Department of Public Health
Brivibas str. 72
LV-1011 Riga
Tel: +371 7876080
Fax: +371 7876071
E-mail: dace_viluma@vm.gov.lv

LITHUANIA
Dr. Grazina MIRINAVICIUTE
Public Health Specialist
Centre for Communicable Diseases
Prevention and Control
Kalvariju Str. 153
08221 Vilnius-42
Lithuania
Tel: +370 5 21 59 273
Fax: +370 5 27 78 761
E-mail: g.mirinaviciute@ulpkc.lt

LUXEMBOURG
Dr. Pierrette HUBERTY-KRAU
Médecin-Inspecteur
Inspection Sanitaire
5A, rue de Prague
L-2348 LUXEMBOURG
Tel: 352 4785650
Fax: 352 480323
E-mail: pierrette.huberty-krau@ms.etat.lu

MALTA
Dr. Tanya MELILLO FENECH M.D.MSC(HSM),Dip(HSM)
Principal Medical officer
Disease Surveillance Unit
Department of Public Health
37/39 Rue D’Argens
Msida
Tel: 21322305
Fax:21319243
E-mail: tanya.melillo@gov.mt
NETHERLANDS
Ms Marja ESVELD
Dutch Health Care Inspectorate
Mailaddress:
P.O. Box 16119
2500 BC Den Haag
Visitaddress:
Parnassusplein 5
2511 VX Den Haag
Tel.: +31 70 3405585
Fax.: +31 70 3405394
E-mail: mi.esveld@igz.nl

NORWAY
Jan FUGLESANG MD
Senior Adviser
Directorate for Health and Social Affairs
PO box 7000 St. Olavs plass
N-0130 Oslo
Phone: +47 24163564
Fax: +47 24163581
Mobile: +47 92410061
E-mail: jfu@shdir.no
Web: www.shdir.no

POLAND
Ms Magdalena MACHALA, M.Sc.
National Influenza Center
National Institute of Hygiene
ul. Chocimska 24
00-791 Warsaw, Poland
Tel/Fax (+48-22) 54 21 313
E-mail: nic@pzh.gov.pl

PORTUGAL
Dr. Maria DA GRACA FREITAS
Direccão-Geral da Saúde
Alameda D. Afonso Henriques 45
P-1049-005 Lisboa
Tel: +351/21 843 0500
Fax: +351/21 843 0620
E-mail: gracafreitas@dgsaude.min-saude.pt

REPUBLIC OF MOLDOVA
Dr. P. Grigorievich SKOFERTSA
National Centre of Scientific Practice for Preventive Medicine
Ministry of Health
67A G. Asaki Str.
2028 Chisinau
Republic of Moldova
Tel: +373 22 72 81 16
ROMANIA  
Dr. Irina CODITA  
National Institute of Research Development for Microbiology and Immunology “Cantacuzino”  
Splaiul Independentei Nr 103, Sector V  
Bucharest Romania  
Tel: +40 21 411 42 00  
Fax: +40 21 411 56 72  
E-mail: icodita@cantacuzino.ro

RUSSIAN FEDERATION  
Dr. Oleg I. KISSELEV  
Director  
Research Institute of Influenza (RAMS)  
Russian Medical Academy of Science  
St. Petersburg  
Prof. Popor Str 15/17  
Tel: +7812 234 6200  
Fax: +7812 234 5973  
E-mail: office@influenza.spb.ru

SAN MARINO  
Dr. Andrea GUALTIERI  
Doctor of Public Health  
Ministère de la santé, de la Sécurité sociale, de l’Assurance nationale, des Affaires sociales et de l’Egalité des chances  
Via Ca’ Giello 12  
San Marino Città  
San Marino  
Tel: +378 0549 883 044  
Fax: +378 0549 883 044  
E-mail: g.andrea@omniway.sm

SERBIA AND MONTENEGRO  
Dr. Dragan LAUSEVIC  
Head Center for Epidemiology  
Institute of Public Health of Montenegro  
Ljubljanska bb  
81000 Podgorica  
Serbia and Montenegro  
Tel: +381 67 335 176  
Fax: +381 81 243 728  
E-mail: epid.iph.mn@cg.yu

Dr. Mila VUCIC-JANKOVIC  
National EPI Manager  
Head of Center for Prevention and Control of Infectious Diseases  
Institute of Public Health of Serbia  
5 Dr Subotica Str.  
11000 Belgrade  
Serbia and Montenegro  
Tel: +381 112 684 566/132  
Fax: +381 112 684 140  
E-mail: vakcine@batut.org.yu
SLOVAKIA
Dr. Margareta SLACIKOVA
Department of Infectious Disease Control
Public Health Authority of the Slovak Republic
Trnavska 52
826 45 Bratislava
Tel: +421 2 492 84 328
Fax: +421 2 443 72 641
E-mail: slacikova@uvzsr.sk

SLOVENIA
Ms Eva GRILC MD
Communicable Diseases Centre, Institute of Public Health of Slovenia
Trubarjeva 2
SI-1000 Ljubljana
Tel: + 386 1 2441 470
E-mail: eva.grilc@ivz-rs.si

SPAIN
Dr. Carmen AMELA HERAS
Technical Advisor
General Direction of Public Health
Centro Nacional de Epidemiologia
Ministry of Health
Paseo Prado 18-20
Madrid 28071
Spain
Tel: +34 91 5961145
Fax: +34 91 5964195
E-mail: camela@msc.es

Ms Maria Jose SIERRA MOROS
Jefa Servicio
Subdireccion General de Promocion de la Salud y Epidemiologia
Ministerio de Sanidad y Consumo
Paseo del Prado, 18-20
28071 Madrid
Spain
Tel: +34 91-596-4386
Fax: +34 91-596-4195
E-mail: jsierra@msc.es

SWEDEN
Dr. Anders TEGNELL
Senior Medical Officer
Communicable Disease Unit
SoS, National Board of Health and Welfare
Stockholm
Sweden
Tel: +46 8 5555 3403, Mobile +46 70 24 50 165
Fax: +46 8 5555 3555
E-mail anders.tegnell@sos.se
SWITZERLAND
Dr. Hans C. MATTER
Deputy Head
Division of Communicable Diseases
Swiss Federal Office of Public Health, SFOPH
CH-3003 Berne
Switzerland
Tel: +41 31 323 87 06
Fax: +41 31 323 87 95
E-mail: Hans.Matter@bag.admin.ch

TAJIKISTAN
Dr. Aliev SAMARDIN
Head Physician
Republican Sanitary and Epidemiological Centre
Chanaeva Str. 8
Dushanbe
Tajikistan
Tel: +992 372 231 860
Fax: +992 372 214 871
E-mail: lotjk.who@tajnet.com

THE FORMER REPUBLIC OF MACEDONIA
Dr. Zarko KARADZOVSKI
Head
Department for Epidemiology and Microbiology
Public Health Institute
50 Divizija Str. No. 6
1000 Skopje
The former Yugoslav Republic of Macedonia
Tel: +389 2 3 125 044
Fax: +389 2 3 223 354
E-mail: zkaradzovski@sonet.com.mk

Dr. Golubinka BOSEVSKA
Specialist in Microbiology
Republic Institute for Health Protection
50 Divizija Str. No. 6
1000 Skopje
The former Yugoslav Republic of Macedónia
Tel: +389 2 3125 044
Fax: +389 2 3223 354
E-mail: golubinka@yahoo.com
**TURKEY**
Dr. Yildirim BAYAZIT  
Chief  
EPI and Vaccine Preventable Disease Unit  
General Directorate of PHC  
Ministry of Health  
Saglik Bakanligi  
06434 Sihhiye-Ankara  
Turkey  
Tel: +90 312 435 3215  
Fax: +90 312 432 2994  
E-mail: ybayazit@saglik.gov.tr

**UKRAINE**
Ms Nina KOSTIUCHENKO  
Chief Specialist  
Infectious Disease Prevention Department  
Dept of State Epidemic Surveillance  
Ministry of Health  
7 M. Hrushevsky Str.  
01021 Kiev  
Ukraine  
Tel: +380 44 253 5203  
Fax: +380 44 253 4932  
E-mail: hlpco@who.org.ua

**UNITED KINGDOM**
Jane LEESER FRCP  
Senior Medical Officer  
Communicable Diseases Branch  
605A Skipton House  
80 London Road  
GB-London SE1 6LH  
Tel: +44 20 7972 1526  
Fax: +44 20 7972 5758  
E-mail: Jane.Leese@doh.gsi.gov.uk

**UZBEKISTAN**
Dr. Erkin MUSABAIEV  
Scientific Research Institute of Virology  
7 Muradov Str.  
700194 Tashkent  
Uzbekistan  
Tel: +998 711 33 50 86  
Fax: +998 711 23 90 69  
E-mail: reflab@sarkor.uz
EPHA  
Ms Anne HOEL  
Policy Assistant  
European Public Health Alliance (EPHA) - the NGO Health Network  
39-41 rue d’Arlon  
B-1000 Brussels  
Tel: +32 2 233 3889  
Fax: +32 2 233 3880  
E-mail: intern2@epha.org  
Website: www.epha.org

EMEA  
Mr Patrick CELIS  
EMEA  
7 Westferry Circus  
Canary Wharf  
London E14 4HB  
Email: Patrick.Celis@emea.eu.int

EISS  
Caroline BROWN, PhD  
Virology Coordinator  
European Influenza Surveillance Scheme co-ordination centre  
at the Netherlands Institute for Health Services Research (NIVEL)  
P.O. Box 1568  
3500 BN Utrecht  
The Netherlands  
Visitor/courier address:  
Drieharingstraat 6  
3511 BJ Utrecht  
Tel: ++31 30 2729849 (direct at NIVEL, Tue, Wed, Thur)  
Fax: ++31 30 2729729 (at NIVEL)  
E-mail: c.brown@nivel.nl

OBSERVER UNMIK  
Professor Naser RAMADANI  
Director  
Department of Epidemiology  
National Institute of Public Health  
Mother Theresa Street nn.  
Pristina, Kosovo-UNMIK  
Tel: +377 44 135 213  
Fax: +381 38 549 217  
E-mail: naser_ramadani@hotmail.com

RAPPORTEUR  
Dr. Babatunde OLOWOKURE  
Regional Surveillance Unit  
Health Protection Agency West Midlands  
Birmingham Heartlands Hospital  
Bordsley Green East, Bordsley Green  
Birmingham  B9 5SS  
United Kingdom of Great Britain and Northern Ireland  
Tel: +44 121 773 7077  
E-mail: BOlowokure@PHLS.org.uk
JOURNALIST
Ms Pam DAS
Senior Editor
The Lancet Infectious Diseases
32 Jamestown Road
NW1 7BY-London
United Kingdom of Great Britain and Northern Ireland
Tel: +44 20 7424 4958
Fax: +44 20 7424 4911
E-mail: Pamela.Das@lancet.com

INTERPRETERS
Mr Georgy G. PIGNASTYY
Conference Interpreter/Translator
152 Leninsky Prosp. Apt. 41
119571 Moscow
Russian Federation
Tel: +7 095 130 62 84
E-mail: epignastyy@yahoo.com, g.pignastyy@who.org.ru

Mr Vladimir M. ILYUKHIN
Simultaneous Interpreter
Nikoloyamskij per. 3A, korpus 4, kv 88
109004 Moscow
Russian Federation
Tel: +7 095 773 7287
E-mail: vladimirilyukhin@yahoo.com, larisab@orc.ru

LUXEMBOURG PRESIDENCY
Dr. Danielle HANSEN-KÖNIG
Directeur de la Santé
Direction de la santé
Villa Louvigny, Allée Marconi
L-2120 Luxembourg
Luxembourg

TEMPORARY ADVISERS
Mr Jonathan VAN TAM
Consultant Epidemiologist (Influenza/Respiratory Virus Infections)
Health Protection Agency
Centre of Infections
61 Colindale Avenue
UK-London NW9 5EQ
Tel: +44 208 327 7689
E-mail: jonathan.vantam@hpa.org.uk

Ms Jill SCIBERRAS
Senior Epidemiologist
Immunization and Respiratory Infections
Division
Centre for Infectious Disease Prevention and Control, Public Health Agency of CAN
Aurora, Ontario, L4G 5J8
Canada
Tel: +1 905 841 2544
E-mail jill_sciberras@phac-aspc.gc.ca
**Professor Ian David GUST**  
Professorial Fellow  
Department of Microbiology and Immunology  
University of Melbourne  
3010 Melbourne, Parkville  
Australia  
Tel: +61 3 83 443 963  
E-mail: idg@unimelb.edu.au  

**WHO Regional Office for Europe**  
**Dr Bernardus GANTER**  
Regional Adviser  
Communicable Disease Surveillance and Response  
WHO Regional Office for Europe  
8 Scherfigsvej  
DK-2100 Copenhagen O  
Denmark  
Tel: +45 39 17 13 98  
E-mail: bga@who.dk  

**Dr Peet TÜLL**  
Medical Officer  
Communicable Disease Surveillance and Response  
WHO Regional Office for Europe  
8 Scherfigsvej  
DK-2100 Copenhagen O  
Denmark  
Tel: +45 39 17 14 40  
E-mail: ptu@who.dk  

**Ms Anne-Marie ANDERSEN**  
Programme Assistant  
Communicable Disease Surveillance and Response  
WHO Regional Office for Europe  
8 Scherfigsvej  
DK-2100 Copenhagen O  
Tel: +45 39 17 14 90  
Fax: +45 39 17 18 69  
E-mail: ama@euro.who.int  

**WHO HEADQUARTERS**  
**Dr Klaus STÖHR**  
Team Coordinator  
WHO Global Influenza Programme, WHO/CDS/CSR/GIP  
Department for Communicable Disease Surveillance and Response  
1211 Geneva 27  
Switzerland  
Tel: + 41 22 791 3004 or 2529  
Fax: +41 22 791 4878 or 4498  
E-mail: stohrk@who.int
DG SANCO  
Dr Georgios GOUVRAS  
Head of Unit  
C3- Health Threats Unit  
Directorate for Public Health and Risk Assessment  
DG SANCO  
European Commission  
Tel: +352 4301 33465  
Fax: +352 4301 33449  
E-mail: georgios.gouvras@cec.eu.int

Dr Massimo CIOTTI  
C3- Health Threats Unit  
Directorate for Public Health and Risk Assessment  
DG SANCO  
European Commission  
Tel: +352 4301 33631  
Fax: +352 4301 33449  
E-mail: massimo.ciotti@cec.eu.int

Mr Franz KARCHER  
C3- Health Threats Unit  
Directorate for Public Health and Risk Assessment  
DG SANCO  
European Commission  
Tel: +352 4301 33162  
Fax: +352 4301 33449  
E-mail: franz.karcher@cec.eu.int

Mr Jan HENDRIKS  
C3- Health Threats Unit  
Directorate for Public Health and Risk Assessment  
DG SANCO  
European Commission  
Tel: +352 4301 32212  
Fax: +352 4301 33449  
E-mail: jan.hendriks@cec.eu.int

Ms Sandra FRANKE  
C3- Health Threats Unit  
Directorate for Public Health and Risk Assessment  
DG SANCO  
European Commission  
Tel: +352 4301 36068  
Fax: +352 4301 33449  
E-mail: sandra.franke@cec.eu.int